Among the cancer type study, CCL8/21 was altered in 1/3 (33%) patients with Paget disease of the nipple, 2/6 (30%) with invasive breast carcinoma, 74/723 (10.24%) with breast invasive ductal carcinoma, 8/192 (4.65%) with breast invasive lobular carcinoma, and 1/27 (3.7%) with breast invasive mixed ductal lobular carcinoma (Figure 7B). Here, CCL8 is linked to invasive ductal breast carcinoma.